Drugs / GT20029
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05428449 | Feb → Oct 2022 | acne, androgenetic alopecia | Suzhou Kintor Pharmaceutical Inc | Completed | No outcome recorded |
| Phase 1 | NCT06468579 | Jul 2021 → Aug 2022 | acne, alopecia | Suzhou Kintor Pharmaceutical Inc | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT06692465 | Apr → Dec 2023 | baldness, male pattern | Suzhou Kintor Pharmaceutical Inc | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GT20029 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06468579 ↗ |
| Action | Inhibit | “GT20029 is a new investigational androgen receptor (AR) degrader” NCT06468579 ↗ |
| Route | Topical | “following topical single and multiple ascending dose administration” NCT05428449 ↗ |
| Target | AR | “androgen receptor (AR) degrader” NCT06692465 ↗ |